Article in Journal of human immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
Chen WangLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID https://orcid.org/0000-0003-4055-7391
Meera PatelLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID https://orcid.org/0009-0003-4473-0320
Celeste G NelsonLaboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID https://orcid.org/0000-0002-2304-9486
Thomas DiMaggioLaboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID https://orcid.org/0000-0002-3051-5553
Theo HellerTranslational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.ORCID https://orcid.org/0000-0002-2643-6289
Edward W CowenDermatology Consultation Service, Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID https://orcid.org/0000-0003-1918-4324
Heidi H KongCutaneous Microbiome and Inflammation Section, Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID https://orcid.org/0000-0003-4424-064X
Heather A KenneyLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID https://orcid.org/0009-0006-7009-2547
Enrico SantangeliLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID https://orcid.org/0009-0002-2983-2866
Yanhan WangDivision of Allergy & Immunology, Department of Medicine, University of California San Diego, Veterans Affairs San Diego Healthcare System, La Jolla, CA, USA.ORCID https://orcid.org/0000-0001-6935-0971
Crhistian Toribio-DionicioDivision of Allergy & Immunology, Department of Medicine, University of California San Diego, Veterans Affairs San Diego Healthcare System, La Jolla, CA, USA.ORCID https://orcid.org/0000-0002-3198-5549
Nicole Akar-GhibrilDivision of Immunology, Allergy and Rheumatology, Joe DiMaggio Children's Hospital, Memorial Healthcare System, Hollywood, FL, USA.ORCID https://orcid.org/0000-0002-3884-081X
Corina E GonzalezImmune Deficiency Cellular Therapy Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID https://orcid.org/0000-0003-0169-9805
Steven M HollandLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID https://orcid.org/0000-0003-3207-5464
Luigi D NotarangeloLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID https://orcid.org/0000-0002-8335-0262
Jonathan J LyonsDivision of Allergy & Immunology, Department of Medicine, University of California San Diego, Veterans Affairs San Diego Healthcare System, La Jolla, CA, USA.ORCID https://orcid.org/0000-0002-2346-8189
Alexandra F FreemanLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID https://orcid.org/0000-0001-7005-8345
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
TPSAB1-derived tryptases promote myeloproliferation and anaphylaxisR00AI138586 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jonathan Lyons · 2024 to 2026
$2.3M
NIAID NIH HHS R00 AI138586NIH HHS 75N91019D00024
6 · The paper itself
Abstract
PGM3 deficiency is a multisystem disorder characterized by recurrent infections, chronic severe neutropenia, and virus-associated malignancies, often leading to premature mortality in early adulthood. These features strongly support early consideration of hematopoietic stem cell transplantation in affected individuals.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Extended clinical phenotypes and long-term outcomes of phosphoglucomutase-3 deficiency. · full record | Socratic